Lilly Looks For Japan Rebound After Hit From LOEs
Executive Summary
Although Lilly Japan's 2022 sales declined 13% on the losses of exclusivity for two important products, the subsidiary has high hopes for three new drugs and other indication expansions. Its first-ever decentralized clinical trial involving Japanese patients, for Alzheimer's candidate donanemab, also turned out successfully.
You may also be interested in...
Lilly’s Latest Leadership Shuffle Gives CSO Skovronsky Immunology Oversight
Lilly Diabetes president Mike Mason is retiring, prompting a shifting of responsibilities among the executive team as the company gears up for key product approvals.
Japan Committee Recommends Lecanemab Approval
An advisory committee of Japan’s MHLW has given a favorable opinion for the approval of Eisai's Alzheimer's drug lecanemab, setting the stage for a possible full official approval in September, after which it would be co-commercialized with global partner Biogen.
Japan Committee Recommends Lecanemab Approval
An advisory committee of Japan’s MHLW has given a favourable opinion for the approval of Eisai's Alzheimer's drug lecanemab, setting the stage for a possible full official approval in September, after which it would be co-commercialized with global partner Biogen.